

Patent Application
Attorney Docket No. PC25301A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 16th day of January, 2004.

By

Kelly A. Smith

(Signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Satoru Iguchi, et al. :

APPLICATION NO.: 10/667,188 : Examiner:

FILING DATE: September 17, 2003 : Group Art Unit: 1625

TITLE: IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4:
RECEPTOR AGONISTS

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 (b)

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.


Date: January 16, 2004

Respectfully submitted,

Christine S. Lee
Christine S. Lee
Attorney for Applicant(s)
Reg. No. 42,788

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-2144


#67318 v1 - PC25301A INFORMATION DISCLOSURE STATEMENT



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC25301A		SERIAL NO. 10/667,188			
									APPLICANT Satoru Iguchi, et al.					
									FILING DATE September 17, 2003		GROUP 1625			
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	5	2	6	0	3	9	3						
	US	5	6	0	4	2	3	9						
	US	5	5	3	1	7	4	9						
	US	5	2	1	9	8	5	0						
	US	5	1	3	0	1	9	1						
	US	5	1	3	7	8	9	3						
	US	0	1	9	5	5	4	7						
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	6	0	5	1	6	5	02/22/96	International				
	WO	9	2	1	5	5	9	3	09/17/92	International				
	EP	9	5	0	4	6	7	3	09/23/92	European				
	WO	9	4	0	8	9	9	8	04/28/94	International				
	JP	2001	0	0	6	8	7	7	01/12/01	Japanese (ABSTRACT IN ENGLISH)				X
	WO	0	1	0	5	7	6	0	01/25/01	International				
	WO	9	5	5	0	2	4	7	10/07/99	International				
	WO	9	7	2	7	7	5	2	08/07/97	International				
	WO	9	7	3	8	6	6	5	10/23/97	International				
	EP	0	2	7	7	7	6	7	4/13/94	European				
	JP	H01	2	5	8	6	7	4	10/16/89	Japanese (ABSTRACT IN ENGLISH)				x
	JP	H02	6	4	3	2	7	4	10/16/89	Japanese (ABSTRACT IN ENGLISH)				X



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25301A	SERIAL NO. 10/667,188
		APPLICANT Satoru Iguchi, et al.	
		FILING DATE September 17, 2003	GROUP 1625
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
		Dumuis, et al., "A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205 930", <i>European Journal of Pharmacology</i> , 146 (1988), 187-188	
		Dumuis, et al., "The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classican 5-HT receptor (5-HT ₄) positively coupled to adenylate cyclase in neurons", <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> (1989) 340: 403- 410	
		Bockaert, et al., "The 5-HT ₄ receptor: a place in the sun", <i>TiPs</i> , 1992, 13, 141-145	
		Ford, A.P.D.W., et al., "The 5-HT ₄ Receptor", <i>Med. Res. Rev.</i> , 1993, 13, 633-662	
		Gullikson, G.W., et al., "Gastrointestinal Motility Responses to the S and R Enantiomers of Zacopride, a 5-HT ₄ Agonist and 5-HT ₃ Antagonist", <i>Drug Dev. Res.</i> , 1992, 26, 405-417	
		Eglen, et al., "Central 5-HT ₄ receptors", <i>TiPs</i> , 1995, 16, 391-398	
		Bockaert, Jr., et al., "5-HT ₄ Receptors Potential Therapeutic Implications in Neurology and Psychiatry", <i>CNS Drugs</i> , 1(1):6-15, 1994	
		Romanelli, M.N., et al., "Synthesis and Biological Activity of a Series of Aryl Tropanyl Esters and Amides Chemically Related to 1H-Indole-3-carboxylic Acid endo 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl Ester", <i>Arzneimittel Forschung Drug Research</i> , 1993, 43, 913-918	
		Kaumann, A., et al., "A 5-HT ₄ -like receptor in human right atrium", <i>Naunyn-Schmiedeberg's Arc., Pharmacol.</i> (1991), 344, 150-159	
		Cavero, et al., "Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias", <i>Expert Opinion of Pharmacotherapy</i> , (2000), 1(5): 947-973	
		Finlayson, K., et al., "[³ H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen", <i>European Journal of Pharmacology</i> , 430, (2001), 147-148	
		Mutterer, v.F., et al., "Halogenierte Pyridine V. Fluorierte und bromierte Pyridinverbindungen", <i>Helv. Chim. Acta</i> , (1976), 59, 229-235	
		Barlow, M.G., et al., "Diels-Alder reactions of trichloro-1,2,4-triazine: intramolecular additions with 1,5 and 1,6 dienes ¹ ", <i>J. Chem. Soc., Perkin Trans. I</i> , (1996), 519-524	
		Lantos, I., et al., "Novel Cage Compounds from Inter-intra-molecular Diels-Alder Reactions of 1,2,4-Triazines with Cyclo-octa-1,5-diene", <i>J. Chem. Soc., Chem. Commun.</i> (1998), 1482-1483	
		Feibush, B., et al., "Chiral Separation of Heterocyclic Drugs by HPLC: Solute-Stationary Phase Base-Pair Interactions", <i>J. Am. Chem. Soc.</i> , (1986), 108(12), 3310-3318	
		G.S. Baxter, et al., "5-Hydroxytryptamine ₄ receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae", <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> , (1991), 343, 439-446	
		Yukiko Mine, et al., "Comparison of Effect of Mosapride Citrate and Existing 5-HT ₄ Receptor Agonists on Gastrointestinal Motility <i>In Vivo</i> and <i>In Vitro</i> ", <i>JPET</i> , (1997) 283: 1000-1008	
		Reeves, J.J., et al., "Investigation into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat oesophagus", <i>British Journal of Pharmacology</i> , (1991) 103: 1067-1072	
		Z. Zhou, et al., "Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature", <i>Biophysical Journal</i> , 74, 230-241 (1998)	
		Lopez-Rodriguez, et al., "Benzimidazole Derivatives. Part 1: Synthesis and Structure-Activity Relationships of New Benzimidazole-4-carboxamides and Carboxylates as Potent and Selective 5-HT ₄ Receptor Antagonists", <i>Bioorganic & Medicinal Chemistry</i> , 7 (1999), 2271-2281	



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25301A		SERIAL NO. 10/667,188	
		APPLICANT Satoru Iguchi, et al.			
		FILING DATE September 17, 2003		GROUP 1625	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) - CONTINUED					
			Prugh, et al., "A Simple Method of Protecting a Secondary Amine with tert Butyloxycarbonyl (BOC) in the Presence of a Primary Amine", <i>Synth. Commun.</i> , 1992, 22, 2357-60		
			Klein, et al., "Design of a New Class of Orally Active Fibrinogen Receptor Antagonists", <i>J. Med. Chem.</i> , 1998, 41, 2492-2502		
			Komatsu, et al., "O ₂ -Binding Properties of Double-Sided Porphinatoiron (II)s with Polar Substituents and Their Human Serum Albumin Hybrids", <i>Bull. Chem. Soc. Jpn.</i> , (2001), 74, 1695-1702		
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE